Beyond the Banks: Three Earnings Reports That Actually Tell You Where the Economy Is Headed
Bank earnings dominate the headlines, but Netflix, BlackRock, and J&J report this week too. Here's why those three tell investors more about the real economy.
Everyone’s Watching the Banks. Here’s What They’re Missing.
Six major banks report earnings this week. JPMorgan, Citigroup, Wells Fargo, Goldman Sachs, Bank of America, and Morgan Stanley will flood your feed Monday through Wednesday with net interest margin figures and loan loss provisions. We covered what to watch in bank earnings separately. It’ll be noisy.
Banks matter, sure. But three other earnings reports this week will tell you far more about the actual economy than any bank balance sheet can: Netflix (Thursday), BlackRock (Monday), and Johnson & Johnson (Tuesday).
Together, they cover consumer spending, institutional capital flows, and healthcare resilience. Three sectors, three economic stress tests, one week.
Can Netflix Raise Prices When Tariffs Are Already Squeezing Wallets?
Netflix reports Thursday after the close. Wall Street expects $12.17 billion in revenue and $0.76 in EPS, roughly 15% growth on both lines. Solid numbers on the surface.
But the headline beat or miss isn’t the story. Three sub-metrics matter more.
First: subscriber retention after the March price hikes. Netflix raised prices across all tiers last month. The ad plan went from $7.99 to $8.99, Standard jumped to $19.99, and Premium hit $26.99.
That’s an extra $1 to $2 per month hitting consumers who are already absorbing an estimated $400 to $600 per year in new tariff costs. The net add number will be the tell.
Second: the ad-tier trajectory. Netflix’s advertising business hit 190 million monthly active viewers globally, with 40% of new signups choosing the ad-supported plan. Ad revenue was roughly $1.5 billion in 2025 and is expected to double to $3 billion this year. If that ramp is on track, it changes the revenue quality story entirely.
Third: operating margin. Netflix is targeting 31.5% for full-year 2026, up from 29.5% in 2025, while boosting content spend 10% to $20 billion. Expanding margins while spending more is hard to sustain. Investors will want to see if management holds or raises that guide.
The stock sits around $103, and 37 of 51 analysts rate it a Buy or Strong Buy. A lot of optimism is already baked in.
BlackRock’s Earnings Are Really a Private Credit Stress Test
BlackRock reports Monday before the bell. Consensus is $12.01 EPS on $6.6 billion in revenue, with AUM expected at $14.21 trillion. Those top-line numbers will probably look fine. iShares ETF flows were record-breaking in 2025.
The real story is in the alternatives business, specifically private credit.
In March, BlackRock capped redemptions on its $26 billion HPS Corporate Lending Fund at 5% after investors requested 9.3% of their shares back. Its $7 billion Tactical Private Credit Fund paid out roughly $240 million against $750 million in requests.
The entire private credit industry is feeling the pressure. Blue Owl issued IOUs. Blackstone injected $400 million of its own capital.
This is a liquidity squeeze in a $2.1 trillion market. We wrote about the broader private credit redemption crisis earlier this week.
Larry Fink himself told investors that CEOs believe the U.S. is likely already in a recession and warned markets could fall another 20%. The earnings call will be worth monitoring for his updated outlook on private credit health, whether outflows are stabilizing, and whether the alternatives platform that grew AUM from $212 billion to $323 billion in 2025 can sustain that growth under stress.
Johnson & Johnson: The Quiet Outperformer So Far in 2026
J&J reports Tuesday before the bell. Wall Street expects $2.68 EPS and $23.4 billion in revenue. The numbers look unremarkable until you zoom out.
J&J has quietly become one of the best-performing mega-caps of 2026, up roughly 15% year-to-date while the S&P 500 struggles. The company is guiding for $99.5 to $100.5 billion in full-year revenue, the first time it would clear $100 billion as a standalone healthcare firm.
Three drivers to watch:
| Driver | Detail |
|---|---|
| Stelara patent cliff absorbed | Biosimilar competition hit 41% of Stelara sales in 2025, but Tremfya grew 65% (from $3.6B to $5.2B) to fill the gap |
| MedTech scaling | $34B in 2025 sales; cardiovascular segment up 15.8% |
| Oncology pipeline advancing | Darzalex Faspro + Tecvayli combo approved March 5, 2026; J&J targeting #1 oncology by 2030 |
The risk side is real, though. J&J faces 67,115 consolidated talc claims with mediation ordered for this month. A $50 million verdict hit in March and the $1.5 billion Baltimore verdict still looms. Tariff costs of roughly $500 million could also pressure MedTech margins.
The Data Calendar That Frames Everything
These earnings don’t exist in a vacuum. The week’s economic releases will set the mood.
| Date | Release | Why It Matters |
|---|---|---|
| Sun, April 13 | Existing home sales (March) | Already in: 3.98M annualized, down 3.6%. Slowest March since 2009. Weak demand backdrop confirmed. |
| Mon, April 14 | PPI for March | February PPI was hot at +0.7% MoM. Sticky producer inflation reinforces Fink’s tariff warnings and tests Netflix’s pricing power thesis. |
| Thu, April 16 | Philly Fed Manufacturing | Forecast to drop from 18.1 to 3.3. A sharp decline that could rattle sentiment before Netflix reports after the close. |
| Thu, April 16 | Initial jobless claims | Prior week was 219K, up from 203K. Rising claims on the same morning the Philly Fed falls would paint a grim picture. |
If PPI comes in hot Monday morning alongside BlackRock’s results, expect the inflation and recession narrative to dominate. If claims spike Thursday alongside a Philly Fed collapse, Netflix’s after-hours report will land in a market already on edge.
The Bigger Picture
S&P 500 Q1 2026 earnings growth is expected at +12.6% year-over-year, which would mark the sixth straight quarter of double-digit growth. But tech sector revenue is growing at 22.5% versus 5.6% for the rest of the S&P 500. That gap matters. The broad market is more fragile than the headline number suggests.
Netflix, BlackRock, and J&J each test a different pressure point: consumer willingness to pay, institutional liquidity, and defensive sector durability. In a week where headlines will chase JPMorgan’s results, the full calendar tells a more complete story about where the economy actually stands.
The information in this post reflects conditions and expectations as of the publication date. Forward-looking statements, including earnings estimates, revenue projections, margin targets, and economic forecasts, are based on current analyst consensus and company guidance. Actual results may differ materially due to changes in economic conditions, company performance, regulatory actions, or other factors.
Ferrante Capital LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Past performance is not indicative of future results.
Disclosure: This article discusses Netflix (NFLX), BlackRock (BLK), and Johnson & Johnson (JNJ). Ferrante Capital, its principals, or its clients may hold positions in these or related securities. This discussion does not constitute a recommendation to buy or sell any security.
Forward-looking statements reflect current views and are subject to change without notice and to material risk. Past performance does not guarantee future results.
Ferrante Capital LLC is a registered investment adviser. Information presented is for educational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal.
FC and its principals may hold positions in securities or asset classes discussed in this article. This analysis is for educational purposes only and does not constitute a recommendation to buy, sell, or hold any security.
Forward-looking statements reflect Ferrante Capital’s current analysis and involve assumptions and estimates. Actual results may differ materially. Past performance is not indicative of future results.
Please consult a qualified financial professional before making investment decisions.
